While they may help create healthier habits, some weight may be regained if treatment is stopped
Medical evaluation and documentation: Your Klarity provider documents your obesity diagnosis, BMI, relevant comorbidities, and treatment rationale the clinical foundation needed for prior authorization if required by your Cigna plan
After 36 weeks, the 0.5 mg retatrutide group showed a 3.19% body weight reduction, the 4 mg group showed a 10.37% decrease, the 8 and 12 mg groups demonstrated decreases of 16.81% and 16.94% respectively, which were significantly greater than those observed with placebo (3.00%) and 1.5 mg dulaglutide (2.02%) [114]
One phase 3 clinical trial found that survodutide led to an average 12% to 18.7% body weight reduction , depending on dose, in adults with obesity and without diabetes after 76 weeks compared to 5% in the placebo group